ArticlePlanta2026
Engineering cotton with ASAL and MYB genes confer dual benefits of pest resistance and fiber improvement.
Article in Planta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MAIN
conclusionThe MYB-ASAL strategy is a promising integrated approach for developing cotton cultivars with enhanced fiber quality and reduced pesticide resistance, strengthening the textile security. The quality of cotton fiber is a critical determinant in the textile industry, significantly influencing the overall quality of textile products. Environmental stressors, particularly extreme climatic conditions, adversely affect fiber quality. This study aims to investigate the enhancement of fiber traits by expressing the transcription factor MYB involved in fiber quality along with the implementation of crop protection strategies and by expressing the plant lectin gene ASAL, which provides resistance against sap-sucking insects. The MYB-ASAL gene cassette was ligated into plant expression vector pCAMBIA1302 which was confirmed through restriction digestion. The Agrobacterium-mediated transformation of pCAMBIA1302_MYB-ASAL cassette in cotton plants was performed through the shoot apex cut method with 1.61% transformation efficiency. The putative transgenic cotton plants were screened through PCR and amplification of 400 bp and 551 bp confirmed the presence of pCAMBIA1302_MYB-ASAL in cotton plants (AI 01-AI 10), which were then tested for mRNA expression. Out of ten transgenic plants, AI 01, AI 03, AI 07, AI 09 and AI 10 showed higher expression (7 and 8 folds) of the MYB gene in boll and leaf, respectively. The mRNA expression level of the MYB gene in T1 generation was higher in early developmental fiber stages, i.e., at 0, 3 and 6 post-anthesis (DPA). The relative MYB expression was high in sepals followed by petals, leaf, boll and seeds, while the mRNA expression of ASAL was significantly high in leaves of AI 03 and AI 09 transgenic cotton lines as compared to control. The whitefly mortality was calculated to be 78% and 80% in T0 and T1, respectively, while 10-15% in control plants. Maximum improvement in fiber length was 20.01%, in the fiber strength up to 17.1% and in the micronaire value up to 16.2% in AI 03 and AI 09 transgenic cotton lines. Scanning electron microscopy (SEM) revealed that the fibers of the transgenic cotton plants have greater number of twists per unit length than the fibers of the non-transgenic control plants. Improved morphological, physiological and biochemical characteristics revealed that MYB-ASAL has a positive impact on these characteristics. Furthermore, single gene copy number was found at chromosome number 4. These findings support the concept of utilizing these transgenic plants to integrate additional desirable traits through breeding strategies, thereby optimizing cotton fiber enhancement.
Indexed as
Identifiers
42873289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.